

ASX/Media Release

18 July 2019

Results of General Meeting

Perth 18 July 2019: Medical dermatology company Botanix Pharmaceuticals Limited (“Botanix” or the “Company”) advises that a General Meeting of the Company was held today, 18 July 2019. All resolutions put to the meeting were passed on a show of hands. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the Company advises that details of the resolutions and the proxies received in respect of each resolution are set out below:

	Resolutions	For	Against	At Proxy Holders Discretion	Abstain/ Excluded
1	Grant of Incentive Options to Vincent Ippolito	102,926,056	4,016,469	1,287,753	87,168,554
2	Approval of potential termination benefit in relation to Incentive Options	187,950,676	5,969,652	1,306,593	171,911
3	Approval of potential termination benefit in relation to certain payments.	187,951,977	5,999,292	1,306,593	140,970
4	Grant of Incentive Options to Michael Thurn	102,869,716	4,025,969	1,342,733	87,160,394

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a clinical stage cannabinoid company based in Perth (Australia) and Philadelphia (USA) committed to the development of pharmaceutical products that are underpinned by science and supported by well-controlled randomised clinical trials. The Company’s focus is the development of safe and effective topical treatments for acne, psoriasis, atopic dermatitis and other skin conditions, together with a development platform of antimicrobial drug candidates. The active ingredient contained in Botanix products is a synthetic form of cannabidiol. Treatment targets for skin diseases include inflammation, deterioration of the of the skin barrier, skin cell proliferation, pruritus (itch), excess sebum production and bacterial infection.

Botanix has an exclusive license to use a proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases. Botanix is working with multiple parties to test the application of Permetrex™ on both a fee-for-service and traditional license basis. Botanix pursues a rapid clinical development strategy aimed at accelerating product commercialisation.

The Company completed its first acne patient studies with BTX 1503 in January 2018 and has commenced a Phase 2 clinical study in June 2018 with study completion expected in 3Q CY2019. The BTX 1204 atopic dermatitis Phase 2 patient study is also underway with study completion expected in 4Q CY2019. A mechanism of action study for Phase 1b BTX 1308 (psoriasis) has recently completed, with positive interim data announced in June 2019. Development of a pipeline of product candidates that leverages the antimicrobial properties of cannabidiol are also moving forward and first products are planned to enter the clinic in 2H CY2019.

To learn more please visit: <https://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Matt Callahan
Botanix Pharmaceuticals
Founder & Executive Director
+1 215 767 4184
mcallahan@botanixpharma.com

Investor enquiries

Joel Seah
Vesparum Capital
P: +61 3 8582 4800
botanixpharma@vesparum.com

Media enquiries

Haley Chartres
Hales² Communications
P: +61 423 139 163
haley@h-squared.com.au